AI Biotech Enveda Doubles in Value to $2 Billion
Covered by 2 sources
Read the full articleEnveda Biosciences, supported by a former Johnson & Johnson CEO, has doubled its valuation to $2 billion as it prepares to advance its drug candidates into late-stage clinical trials.




